Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

NeuroGenetic reports positive results from Phase I trials of NGP 555 to treat Alzheimer’s disease

Go Top